Lijun Zhong

Dr. Lijun Zhong


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2019 in Metabolomics
Verified
Journal Article
Closed access
PDF file
LTLianyuan Tao
Lianyuan Tao
JZJuntuo Zhou
Juntuo Zhou
CYChunhui Yuan
Chunhui Yuan
LZLingfu Zhang
Lingfu Zhang
DLDeyu Li
Deyu Li
LZLijun Zhong
Lijun Zhong

1 March 2017 in Talanta
Verified
Journal Article
Closed access
JZJuntuo Zhou
Juntuo Zhou
YLYuhua Li
Yuhua Li
XCXi Chen
Xi Chen
LZLijun Zhong
Lijun Zhong
YYYuxin Yin
Yuxin Yin

3 November 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
JZJuntuo Zhou
Juntuo Zhou
LZLijun Zhong
Lijun Zhong
Metabolomics is a fast-developing technique used in biomedical researches focusing on pathological mechanism illustration or novel biomarker development for diseases. The ability of simultaneously quantifying thousands of metabolites in samples makes metabolomics a promising technique in predictive or personalized medicine-oriented researches and applications. Liquid chromatography-mass spectrometry is the most widely employed analytical strategy for metabolomics. In this current mini-review, we provide a brief update on the recent developments and novel applications of LC-MS based metabolomics in the predictive and personalized medicine sector, such as early diagnosis, molecular phenotyping or prognostic evaluation. COVID-19 related metabolomic studies are also summarized. We also discuss the prospects of metabolomics in precision medicine-oriented researches, as well as critical issues that need to be addressed when employing metabolomic strategy in clinical applications.

22 October 2020 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
YHYongzheng Han
Yongzheng Han
WZWenchao Zhang
Wenchao Zhang
JLJiao Liu
Jiao Liu
YSYanan Song
Yanan Song
TLTaotao Liu
Taotao Liu
YYYi Yuan
Yi Yuan
Objective To investigate dysregulated molecules in preoperative cerebrospinal fluid (CSF) of elderly hip fracture patients with postoperative delirium (POD), in order to identify potential pathological mechanisms and biomarkers for pre-stage POD. Methods This nested case control study used untargeted metabolomic and lipidomic analysis to profile the preoperative CSF of patients (n = 40) who developed POD undergone hip fracture surgery (n = 10) and those who did not (n = 30). Thirty Non-POD patients were matched to ten POD patients by age (± 2 years) and Mini Mental State Examination score (± 2 points). CSF was collected after successful spinal anesthesia and banked for subsequent analysis. On the first two postoperative days, patients were assessed twice daily using the Confusion Assessment Method-Chinese Revision. CSF samples from the two groups were analyzed to investigate possible relevant pathological mechanisms and identify candidate biomarkers. Results Demographic characteristics of the groups were matched. Eighteen metabolites and thirty-three lipids were dysregulated in the preoperative CSF of POD patients. Pathway enrichment analysis revealed perturbations in D-glutamine and D-glutamate metabolism; glycerophospholipid metabolism; alanine, aspartate and glutamate metabolism; sphingolipid metabolism; histidine metabolism; and arginine biosynthesis at the pre-delirium stage. Receiver operating characteristic curve analysis indicated that phosphatidylethanolamine (PE, 40:7e), with an area under the curve value of 0.92, is a potential biomarker for POD. Conclusion Multiple pathological mechanisms in the POD group were involved before surgery, including neuroinflammation, oxidative stress, and energy metabolism disorders induced by hypoxia, as well as neurotransmitter imbalances such as increased dopamine and glutamate, and decreased glutamine. These metabolic abnormalities potentially increase the fragility of the brain, thus contributing to POD. PE (40:7e) might be a potential biomarker for POD. Not only do our results provide potential biomarkers for POD, but also provide information for deep pathological research. Clinical trial registration: This study was registered in the Chinese Clinical Trial Registry (ChiCTR1900021533).

1 June 2017 in Analytica Chimica Acta
Verified
Journal Article
Closed access
JZJuntuo Zhou
Juntuo Zhou
CLChunlei Liu
Chunlei Liu
DSDandan Si
Dandan Si
BJBing Jia
Bing Jia
LZLijun Zhong
Lijun Zhong
YYYuxin Yin
Yuxin Yin

21 June 2019 in Metabolomics
Verified
Journal Article
Closed access
PDF file
JZJuntuo Zhou
Juntuo Zhou
LSLijie Sun
Lijie Sun
LCLiwen Chen
Liwen Chen
SLShuwang Liu
Shuwang Liu
LZLijun Zhong
Lijun Zhong
CMCui Ming
Cui Ming